NO20073958L - Pyrrolidylderivater av heteroaromatiske forbindelser som fosfodiesteraseinhibitorer - Google Patents

Pyrrolidylderivater av heteroaromatiske forbindelser som fosfodiesteraseinhibitorer

Info

Publication number
NO20073958L
NO20073958L NO20073958A NO20073958A NO20073958L NO 20073958 L NO20073958 L NO 20073958L NO 20073958 A NO20073958 A NO 20073958A NO 20073958 A NO20073958 A NO 20073958A NO 20073958 L NO20073958 L NO 20073958L
Authority
NO
Norway
Prior art keywords
compounds
relates
disorders
phosphodiesterase inhibitors
heteroaromatic compounds
Prior art date
Application number
NO20073958A
Other languages
English (en)
Inventor
Thomas Allen Chappie
John Michael Humphrey
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36046318&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20073958(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of NO20073958L publication Critical patent/NO20073958L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Foreliggende oppfinnelse angår nye pyrrolidylderivater av benzosammensmeltede azaheteroaromatiske forbindelser som tjener som effektive fosfodiesterase (PDE)-inhibitorer. Oppfinnelsen angår også forbindelser som er selektive inhibitorer av PDE-IO. Oppfinnelsen angår videre intermediater for fremstilling av slike forbindelser; farmasøytiske sammensetninger som innbefatter slike forbindelser; og anvendelse av slike forbindelser i fremgangsmåter for behandling av visse sentralnervesystem (CNS) og andre forstyrrelser. Oppfinnelsen angår også fremgangsmåter for behandling av neurodegenerative og psykiatriske forstyrrelser, for eksempel psykose og forstyrrelser som innbefatter svekket kognisjon som et symptom.
NO20073958A 2004-12-31 2007-07-27 Pyrrolidylderivater av heteroaromatiske forbindelser som fosfodiesteraseinhibitorer NO20073958L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US64040504P 2004-12-31 2004-12-31
PCT/IB2005/003989 WO2006070284A1 (en) 2004-12-31 2005-12-19 Pyrrolidyl derivatives of heteroaromatic compounds as phosphodiesterase inhibitors

Publications (1)

Publication Number Publication Date
NO20073958L true NO20073958L (no) 2007-09-27

Family

ID=36046318

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20073958A NO20073958L (no) 2004-12-31 2007-07-27 Pyrrolidylderivater av heteroaromatiske forbindelser som fosfodiesteraseinhibitorer

Country Status (23)

Country Link
US (1) US20060183763A1 (no)
EP (1) EP1838702A1 (no)
JP (1) JP2008526726A (no)
KR (1) KR20070086841A (no)
CN (1) CN101087778A (no)
AP (1) AP2007004004A0 (no)
AR (1) AR055298A1 (no)
AU (1) AU2005321015A1 (no)
BR (1) BRPI0519760A2 (no)
CA (1) CA2594251A1 (no)
CR (1) CR9135A (no)
EA (1) EA200701118A1 (no)
GT (1) GT200500367A (no)
IL (1) IL183188A0 (no)
MA (1) MA29119B1 (no)
MX (1) MX2007006301A (no)
NL (1) NL1030819C2 (no)
NO (1) NO20073958L (no)
PE (1) PE20060775A1 (no)
TN (1) TNSN07248A1 (no)
TW (1) TW200637851A (no)
UY (1) UY29317A1 (no)
WO (1) WO2006070284A1 (no)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101166730A (zh) * 2005-03-01 2008-04-23 惠氏公司 噌啉化合物及其作为肝x受体调节剂的用途
GB0522715D0 (en) 2005-11-08 2005-12-14 Helperby Therapeutics Ltd New use
BRPI0707223A2 (pt) * 2006-01-27 2011-04-26 Pfizer Prod Inc compostos de derivados de aminoftalazina
AU2007217474A1 (en) * 2006-02-21 2007-08-30 Amgen Inc. Cinnoline derivatives as phosphodiesterase 10 inhibitors
AU2007217750A1 (en) * 2006-02-21 2007-08-30 Amgen Inc. Cinnoline derivatives as phosphodiesterase 10 inhibitors
MX2008010953A (es) * 2006-02-28 2008-09-08 Amgen Inc Derivados de cinolina y quinoxalina como inhibidores de la fosfodiesterasa 10.
US20090099175A1 (en) * 2006-03-01 2009-04-16 Arrington Mark P Phosphodiesterase 10 inhibitors
CA2644850A1 (en) * 2006-03-08 2007-09-13 Amgen Inc. Quinoline and isoquinoline derivatives as phosphodiesterase 10 inhibitors
WO2008020302A2 (en) * 2006-08-17 2008-02-21 Pfizer Products Inc. Heteroaromatic quinoline-based compounds as phosphodiesterase (pde) inhibitors
WO2008142384A1 (en) 2007-05-17 2008-11-27 Helperby Therapeutics Limited Use of 4-(pyrrolidin-1-yl)quinoline compounds to kill clinically latent microorganisms
TWI501965B (zh) * 2008-06-20 2015-10-01 Lundbeck & Co As H 作為ｐｄｅ１０ａ酵素抑制劑之新穎苯基咪唑衍生物
US8133897B2 (en) 2008-06-20 2012-03-13 H. Lundbeck A/S Phenylimidazole derivatives as PDE10A enzyme inhibitors
UA102693C2 (ru) * 2008-06-20 2013-08-12 Х. Луннбек А/С Производные фенилимидазола как ингибиторы фермента pde10a
TWI396689B (zh) * 2008-11-14 2013-05-21 Amgen Inc 作為磷酸二酯酶１０抑制劑之吡衍生物
SG171914A1 (en) 2008-12-02 2011-07-28 Chiralgen Ltd Method for the synthesis of phosphorus atom modified nucleic acids
AU2010270714B2 (en) 2009-07-06 2015-08-13 Wave Life Sciences Ltd. Novel nucleic acid prodrugs and methods use thereof
US10428019B2 (en) 2010-09-24 2019-10-01 Wave Life Sciences Ltd. Chiral auxiliaries
DE102010042833B4 (de) 2010-10-22 2018-11-08 Helmholtz-Zentrum Dresden - Rossendorf E.V. Neue Halogenalkoxychinazoline, deren Herstellung und Verwendung
KR20220047894A (ko) * 2010-11-08 2022-04-19 오메로스 코포레이션 Pde7 억제제를 사용한 중독 및 충동-조절 장애의 치료
CN103476757A (zh) 2011-02-18 2013-12-25 阿勒根公司 作为磷酸二酯酶10(pde10a)的抑制剂的取代的6,7-二烷氧基-3-异喹啉醇衍生物
DK2734208T3 (en) 2011-07-19 2017-06-19 Wave Life Sciences Ltd PROCEDURES FOR SYNTHESIS OF FUNCTIONALIZED NUCLEIC ACIDS
WO2013176877A2 (en) * 2012-05-07 2013-11-28 Omeros Corporation Treatment of addiction and impulse-control disorders using pde7 inhibitors
US9598458B2 (en) 2012-07-13 2017-03-21 Wave Life Sciences Japan, Inc. Asymmetric auxiliary group
SG11201500232UA (en) 2012-07-13 2015-04-29 Wave Life Sciences Pte Ltd Chiral control
JP6246121B2 (ja) 2012-07-13 2017-12-13 株式会社新日本科学 キラル核酸アジュバント
WO2014071044A1 (en) 2012-11-01 2014-05-08 Allergan, Inc. Substituted 6,7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (pde10a)
US10154988B2 (en) 2012-11-14 2018-12-18 The Johns Hopkins University Methods and compositions for treating schizophrenia
ITVI20130032A1 (it) * 2013-02-14 2014-08-15 F I S Fabbrica Italiana Sint I S P A Procedimento per la preparazione di n-boc-pirrolidinone
US9200016B2 (en) 2013-12-05 2015-12-01 Allergan, Inc. Substituted 6, 7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (PDE 10A)
JPWO2015108048A1 (ja) 2014-01-15 2017-03-23 株式会社新日本科学 抗腫瘍作用を有するキラル核酸アジュバンド及び抗腫瘍剤
EP3095460A4 (en) 2014-01-15 2017-08-23 Shin Nippon Biomedical Laboratories, Ltd. Chiral nucleic acid adjuvant having anti-allergic activity, and anti-allergic agent
JPWO2015108047A1 (ja) 2014-01-15 2017-03-23 株式会社新日本科学 免疫誘導活性を有するキラル核酸アジュバンド及び免疫誘導活性剤
US10160969B2 (en) 2014-01-16 2018-12-25 Wave Life Sciences Ltd. Chiral design
TW201611834A (en) * 2014-02-07 2016-04-01 Lundbeck & Co As H Hexahydrofuropyrroles as PDE1 inhibitors
JP6554116B2 (ja) * 2014-04-04 2019-07-31 ハー・ルンドベック・アクチエゼルスカベット Ｐｄｅ１阻害剤としてのハロゲン化キナゾリン−ｔｈｆ−アミン
BR112017015760A2 (pt) * 2015-01-23 2018-03-27 Gvk Biosciences Private Limited inibidores de quinase trka
KR20210134838A (ko) 2016-07-14 2021-11-10 크리네틱스 파마슈티칼스, 인크. 소마토스타틴 조절제 및 그의 용도
CN106632089B (zh) * 2016-11-04 2019-06-18 中山大学 一类喹唑啉类化合物及其制备方法与应用
EP3733670A4 (en) * 2017-12-26 2022-01-26 Mediconns (Shanghai) Biopharmaceutical Co., Ltd TETRAHYDROPYRROL COMPOUND, METHOD OF MANUFACTURE THEREOF, PHARMACEUTICAL COMPOSITION THEREOF AND USE THEREOF
EP4210700A1 (en) 2020-09-09 2023-07-19 Crinetics Pharmaceuticals, Inc. Formulations of a somatostatin modulator
CN115417802A (zh) * 2021-05-16 2022-12-02 上海鼎雅药物化学科技有限公司 乌帕替尼及其中间体的制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3577432A (en) * 1968-12-23 1971-05-04 Robins Co Inc A H 1-substituted-3-phenoxypyrrolidines
US4306065A (en) * 1979-12-19 1981-12-15 A. H. Robins Company, Incorporated 2-Aryl-4-substituted quinazolines
US5721237A (en) * 1991-05-10 1998-02-24 Rhone-Poulenc Rorer Pharmaceuticals Inc. Protein tyrosine kinase aryl and heteroaryl quinazoline compounds having selective inhibition of HER-2 autophosphorylation properties
JP3919272B2 (ja) * 1996-12-18 2007-05-23 エーザイ・アール・アンド・ディー・マネジメント株式会社 キナゾリン系化合物
JP2002523413A (ja) * 1998-08-25 2002-07-30 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド ニコチン性アセチルコリン受容体のリガンドとしてのピリジルエーテルおよびチオエーテル、ならびにその治療的用途
US20020151712A1 (en) * 1999-09-14 2002-10-17 Nan-Horng Lin 3-pyrrolidinyloxy-3'-pyridyl ether compounds useful for controlling chemical synaptic transmission
KR100621287B1 (ko) * 2001-05-21 2006-09-13 에프. 호프만-라 로슈 아게 신경 펩타이드 ｙ 수용체에 대한 리간드로서의 퀴놀린유도체
US20070021404A1 (en) * 2003-06-24 2007-01-25 Dan Peters Novel aza-ring derivatives and their use as monoamine neurotransmitter re-uptake inhibitors
US20090162286A1 (en) * 2004-06-07 2009-06-25 Pfizer Inc. Phosphodiesterase 10 Inhibition as Treatment for Obesity-Related and Metabolic Syndrome-Related Conditions

Also Published As

Publication number Publication date
AU2005321015A1 (en) 2006-07-06
NL1030819A1 (nl) 2006-07-03
JP2008526726A (ja) 2008-07-24
NL1030819C2 (nl) 2007-01-04
TNSN07248A1 (fr) 2008-11-21
PE20060775A1 (es) 2006-09-01
WO2006070284A1 (en) 2006-07-06
US20060183763A1 (en) 2006-08-17
AR055298A1 (es) 2007-08-15
IL183188A0 (en) 2007-08-19
UY29317A1 (es) 2006-07-31
AP2007004004A0 (en) 2007-06-30
CA2594251A1 (en) 2006-07-06
EA200701118A1 (ru) 2007-12-28
CN101087778A (zh) 2007-12-12
MA29119B1 (fr) 2007-12-03
TW200637851A (en) 2006-11-01
KR20070086841A (ko) 2007-08-27
MX2007006301A (es) 2007-06-15
GT200500367A (es) 2006-08-16
EP1838702A1 (en) 2007-10-03
BRPI0519760A2 (pt) 2009-03-10
CR9135A (es) 2007-08-14

Similar Documents

Publication Publication Date Title
NO20073958L (no) Pyrrolidylderivater av heteroaromatiske forbindelser som fosfodiesteraseinhibitorer
TW200736246A (en) Bicyclic heteroaryl compounds as PDE10 inhibitors
WO2007085954A3 (en) Aminophthalazine derivative compounds
NO20065948L (no) Quinazolin-4-yl-piperidin- and cinnolin-4-yl-piperidin-derivatives som PDE10-inhibitorer for behandling av CNS forstyrrelser
WO2008001182A8 (en) Tricyclic heteroaryl compounds as pde10 inhibitors
WO2008020302A3 (en) Heteroaromatic quinoline-based compounds as phosphodiesterase (pde) inhibitors
WO2007129183A3 (en) Bicyclic heteroaryl compounds as pde10 inhibitors
TW200637555A (en) Heteroaromatic quinoline compounds
WO2005082883A3 (en) Tetrahydroisoquinolinyl derivatives of quinazoline and isoquinoline
SE0303180D0 (sv) Novel compounds
WO2008045393A3 (en) Imidazo- and triazolo-pyridine compounds and methods of use therof
CY1107747T1 (el) Υποκατεστημενα τετρακυκλικα παραγωγα πυρρολοκινολονης χρησιμα ως αναστολεις της φωσφοδιεστερασης
NO20074959L (no) Substituerte pyridinderivater
MX2007011847A (es) Derivados de pirimidindiona como antagonistas del receptor de procineticina 2.
NO20091463L (no) Heterocyklisk deriverte metalloproteaseinhibitorer
EA200900472A1 (ru) Ингибиторы фосфодиэстеразы iv типа
ATE368666T1 (de) Pyrazolopyrimidinone und ihre verwendung als pde inhibitoren
DK1673354T3 (da) Arylindenopyridiner og arylindenopyrimidiner og deres anvendelse som adenosin-A2a-receptorantagonister
NO20083045L (no) Benzimidazolderivater og deres anvendelse til modulering av GABAA-reseptorkomplekset
NO20075793L (no) Benzimidazolderivater og deres anvendelse for modulering av GABAA - reseptorkomplekset
EA200501594A1 (ru) Замещенные производные азабициклогексана в качестве антагонистов мускаринового рецептора
NO20082459L (no) Nye prosesser for fremstilling av piperazinyl og diazapanylbenzamidderivater
DE602007013079D1 (de) Phthalazin-, aza- und diazaphthalazinverbindungen und anwendungsverfahren
DOP2005000273A (es) Derivados novedosos pirrolidilo de compuestos heteroaromaticos
DOP2007000001A (es) Compuestos de heteroarilo biciclicos como inhibidores de pde10

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application